---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-092268"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:47:16.369485+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics Q2 net loss $25.7M; FDA lifts partial clinical hold on zorevunersen

## Summary
- FDA removed Partial Clinical Hold on zorevunersen for Dravet syndrome; planning Phase 3 registrational study.
- Q2 revenue $4.8M (vs. -$2.5M prior year); net loss $25.7M ($0.46/shr) vs. $30.7M ($0.69/shr) prior year.
- Cash, cash equivalents, and marketable securities totaled $282M as of June 30, 2024.
- On track to initiate Phase 1 OSPREY study of STK-002 for Autosomal Dominant Optic Atrophy in 2024.
- Regulatory discussions ongoing; update on Phase 3 registrational plans for zorevunersen expected H2 2024.

## SEC filing metadata
- accession: 0000950170-24-092268
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000095017024092268/0000950170-24-092268-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000095017024092268/stok-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-092268
- JSON: https://secwatch.observer/filing/0000950170-24-092268.json
- Plain text: https://secwatch.observer/filing/0000950170-24-092268.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.